{
    "organizations": [],
    "uuid": "94d37a6df7a60e911bd76528ff711c6a4fdf76c3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-weill-cor/brief-nanobiotix-partners-with-weill-cornell-medicine-idUSFWN1SA1BN",
    "ord_in_thread": 0,
    "title": "Nanobiotix Partners With Weill Cornell Medicine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - NANOBIOTIX SA:\n* PARTNERS WITH WEILL CORNELL MEDICINE * PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS\n* TRIAL THAT SHALL START IN Q2 2018, AIMS TO EXPAND POTENTIAL OF NBTXR3\n* COLLABORATION WILL BE CONDUCTED OVER COURSE OF 1 YEAR, WITH GOAL OF CONTINUING EXPLORATION OF ROLE OF NBTXR3 IN IMMUNO-ONCOLOGY Source text for Eikon: (Gdynia Newsroom)\nOur ",
    "published": "2018-05-04T01:42:00.000+03:00",
    "crawled": "2018-05-04T16:46:15.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "nanobiotix",
        "sa",
        "partner",
        "weill",
        "cornell",
        "medicine",
        "partnership",
        "study",
        "evaluate",
        "nbtxr3",
        "impact",
        "pathway",
        "mammary",
        "cancer",
        "trial",
        "shall",
        "start",
        "q2",
        "aim",
        "expand",
        "potential",
        "nbtxr3",
        "collaboration",
        "conducted",
        "course",
        "year",
        "goal",
        "continuing",
        "exploration",
        "role",
        "nbtxr3",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}